FRAMINGHAM, MA--(Marketwire - August 14, 2008) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced financial results for the second quarter ended June 30, 2008. For the three months ended June 30, 2008, the Company reported a net loss of $693,074, or $0.04 per share, compared with a net loss of $1,131,151, or $0.09 per share, in the prior year. For the six months ended June 30, 2008, the Company reported a net loss of $1,378,737, or $0.09 per share, compared with a net loss of $2,470,624, or $0.20 per share, in the prior year. The decreased loss for such period resulted primarily from decreased clinical development expenses related to the clinical trials of IoGen™ and investor relations expenses, partially offset by increased stock-based compensation.
